Dr Mehran Jalaie, Pfizer, gave this presentation at “Streamlining Drug Discovery” symposium held in San Diego, CA, USA on 21 April 2017.

Abstract
Picking desirable bioactive compounds for therapeutic projects has been an “artful skill” for decades relying on intuition and previous experience of individuals involved in compound selections on active projects. However, as the frequency of novel targets rises, previous experience on unrelated targets becomes increasingly less likely to be helpful. In recent years, several teams have developed many virtual screening techniques to assist in hit identification, with scoring functions and statistical analysis providing scientific backing and supplementation to designer’s intuitions.
In this presentation, we will share the results of virtual screening campaigns that successfully identified hits and lead series for several projects. The success and efficiency of the lead identification efforts for these projects were driven by availability, sophistication, streamlining of the tools, processes, and the incorporation of best practice methodologies.

You can download this presentation as a PDF.